Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Monica Galli

Showing results (21-30 of 57) with videos related to

Pageof 6
Sort By:
European Journal of Haematology|July 23, 2021
Safety of outpatient stem cell mobilization with low- or intermediate-dose cyclophosphamide in newly diagnosed multiple myeloma patientsAlessandra Pompa, Loredana Pettine, Diana Giannarelli, et al.
British Journal of Haematology|February 14, 2002
Negative selection of peripheral blood stem cells to support a tandem autologous transplantation programme in multiple myelomaAnna Maria Barbui, Monica Galli, Gianpietro Dotti, et al.
American Journal of Hematology|December 23, 2011
Response-adjusted ISS (RaISS) is a simple and reliable prognostic scoring system for predicting progression-free survival in transplanted patients with multiple myelomaAlessandro Corso, Monica Galli, Silvia Mangiacavalli, et al.
British Journal of Haematology|April 9, 2005
Anti-prothrombin IgG from patients with anti-phospholipid antibodies inhibits the inactivation of factor Va by activated protein CMonica Galli, George M Willems, Jan Rosing, et al.
European Journal of Haematology|January 8, 2025
Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM TrialPaul Richardson, Meral Beksaç, Albert Oriol, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 10, 2023
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose AdjustmentAlbert Oriol, Meletios Dimopoulos, Fredrik Schjesvold, et al.
Annals of the Rheumatic Diseases|January 31, 2007
Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studiesSilvia S Pierangeli, Mariano E Vega-Ostertag, Elena Raschi, et al.
Leukemia & Lymphoma|May 4, 2011
Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplantFrancesco Spina, Vittorio Montefusco, Claudia Crippa, et al.
British Journal of Haematology|January 4, 2020
Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapseVittorio Montefusco, Alessandro Corso, Monica Galli, et al.
Leukemia & Lymphoma|April 16, 2014
Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomideVittorio Montefusco, Monica Galli, Francesco Spina, et al.
Pageof 6

Showing results (21-30 of 57) with videos related to

Sort By:
Pageof 6
European Journal of Haematology|July 23, 2021
Safety of outpatient stem cell mobilization with low- or intermediate-dose cyclophosphamide in newly diagnosed multiple myeloma patientsAlessandra Pompa, Loredana Pettine, Diana Giannarelli, et al.
British Journal of Haematology|February 14, 2002
Negative selection of peripheral blood stem cells to support a tandem autologous transplantation programme in multiple myelomaAnna Maria Barbui, Monica Galli, Gianpietro Dotti, et al.
American Journal of Hematology|December 23, 2011
Response-adjusted ISS (RaISS) is a simple and reliable prognostic scoring system for predicting progression-free survival in transplanted patients with multiple myelomaAlessandro Corso, Monica Galli, Silvia Mangiacavalli, et al.
British Journal of Haematology|April 9, 2005
Anti-prothrombin IgG from patients with anti-phospholipid antibodies inhibits the inactivation of factor Va by activated protein CMonica Galli, George M Willems, Jan Rosing, et al.
European Journal of Haematology|January 8, 2025
Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM TrialPaul Richardson, Meral Beksaç, Albert Oriol, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 10, 2023
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose AdjustmentAlbert Oriol, Meletios Dimopoulos, Fredrik Schjesvold, et al.
Annals of the Rheumatic Diseases|January 31, 2007
Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studiesSilvia S Pierangeli, Mariano E Vega-Ostertag, Elena Raschi, et al.
Leukemia & Lymphoma|May 4, 2011
Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplantFrancesco Spina, Vittorio Montefusco, Claudia Crippa, et al.
British Journal of Haematology|January 4, 2020
Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapseVittorio Montefusco, Alessandro Corso, Monica Galli, et al.
Leukemia & Lymphoma|April 16, 2014
Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomideVittorio Montefusco, Monica Galli, Francesco Spina, et al.
Pageof 6